title: Treatment results of osteosarcoma of the extremity in children and adolescents at Ege University Hospital.
abstract: Twenty-five patients were treated for osteosarcoma of the extremity at Ege University Hospital. Eight of them were metastatic. All patients received cisplatin, doxorubicin, ifosfamide, and methotrexate preoperatively. Twenty-three patients underwent surgery at around week 15 (11-18 weeks). All but one underwent limb-sparing surgery. While good responders continued to receive the same drugs, poor responders were given the same regimen before 1996, but high-dose ifosfamide alone after 1996. For all patients the projected event-free survival (EFS) rates were 63.5% at 2 years and 53% at 5 years. The projected overall survival (OS) rates were 72% at 2 years and 62% at 5 years. For nonmetastatic patients, 5-year EFS and OS rates were 67% as compared with metastatic patients (25 and 50%)(p =. 01 for EFS; p > .05 for OS). The results show that nonmetastatic patients with osteosarcoma of the extremity have favorable prognosis on this therapy regimen, allowing a high rate of limb-sparing surgery.
authors.affiliation: Department of Pediatrics, Division of Pediatric Oncology, Ege University School of Medicine, Izmir, Turkey. mkantar@med.ege.edu.tr
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kantar
authors.forename: Nazan
authors.initials: N
authors.lastname: Cetingül
authors.forename: Sertaç
authors.initials: S
authors.lastname: Azarsíz
authors.forename: Savaş
authors.initials: S
authors.lastname: Kansoy
authors.forename: Dündar
authors.initials: D
authors.lastname: Sabah
authors.forename: Ayşenur
authors.initials: A
authors.lastname: Memiş
authors.forename: Gülçin
authors.initials: G
authors.lastname: Başdemir
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Burak
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002648:Child; D018572:Disease-Free Survival; D005121:Extremities / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D023821:Limb Salvage; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy; D008297:Male; D012516:Osteosarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007069:Ifosfamide